Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 4Neoplasm Metastasis 3Leukemia, Myeloid, Acute 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Myelodysplastic Syndromes 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Leukemia, Myelomonocytic, Chronic 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Brain Neoplasms 1Anus Neoplasms 1Advanced Cancer 1

Interventions

Azacitidine 23fludarabine phosphate 17Cyclophosphamide 16Decitabine 12Cytarabine 11Peripheral Blood Stem Cell Transplantation 10Whole-Body Irradiation 9Mycophenolic Acid 9Filgrastim 8Tacrolimus 7Cyclosporine 7venetoclax 6decitabine and cedazuridine drug combination 6fludarabine 5Carboplatin 5sargramostim 4Vorinostat 4Specimen Handling 4Sirolimus 4Radiotherapy 4Injections 4Cyclosporins 4Clofarabine 4Busulfan 4ruxolitinib 3cedazuridine 3aldesleukin 3Topotecan 3Melphalan 3Leucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelomonocytic, Chronic × prexasertib × Clear all
NCT02649764 2023-10-04

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1 Completed
15 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡